Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
NCT ID: NCT04668521
Last Updated: 2023-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
215 participants
OBSERVATIONAL
2020-05-04
2023-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
NCT00291096
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCT00040222
Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer
NCT00276120
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
NCT00823654
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
NCT00899145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COHORT A
Women with a pelvic mass, symptomatic or asymptomatic.
OVA360
Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
COHORT B
Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
OVA360
Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
COHORT C
Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
OVA360
Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OVA360
Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
• Diagnosed with a pelvic mass
* Diagnosed with a pelvic mass
* Undergoing genetic testing through our commercial offering
• Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
Exclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aspira Women's Health
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Todd Pappas, PhD
Role: PRINCIPAL_INVESTIGATOR
Aspira Women's Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Silvana Franco
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.